Veeva：2024年使用Veeva SafeMine 保护隐私、精确的患者数据报告（英文版）

For life sciences companies, the implications are that de-identified patient data is incomplete and erroneous. It does not accurately reflect patient journeys or even the number of patients relevant for a specific Rx product. This can lead to poor understanding of patient needs and inaccurate forecasting